Drug Profile
Melanoma vaccine - MabVax/Memorial Sloan-Kettering Cancer Center
Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 10 May 2016 No recent reports on development identified - Phase-I for Malignant melanoma (Late-stage disease) in USA (Parenteral)
- 08 Jul 2014 MabVax Therapeutics merged with a wholly-owned subsidiary of Telik
- 31 Dec 2007 Phase-I clinical trials in Malignant melanoma in USA (Parenteral)